—

Medline Inc. Class A Common Stock (MDLN) — the peer cohort

As of 2026-10-12 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Medline Inc. Class A Common Stock ranks 9 of 10 in its cohort on the Closelooknet composite (44/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
MDLN Medline Inc. Class A Common Stock 44 19 30 36 — —
FPH.AU Fisher & Paykel Healthcare Corporation Ltd 61 84 70 27 ok 0%
ISRG Intuitive Surgical Inc 58 36 76 21 neutral 29.8%
YPSN.SW Ypsomed Holding AG 56 69 62 28 info 13.7%
TECN.SW Tecan Group AG 48 93 27 52 ok 7.7%
MMED MiniMed Group, Inc. Common Stock 46 77 21 26 — —
EL.PA EssilorLuxottica S. A. 44 9 45 58 bear 53.7%
HALO Halozyme Therapeutics Inc 74 94 94 48 ok 4.9%
DXCM DexCom Inc 66 85 80 35 bull 9.2%
ONC BeiGene, Ltd. 63 76 62 30 info 9%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-12

Quick answers

Who are Medline Inc. Class A Common Stock's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Fisher & Paykel Healthcare Corporation Ltd (FPH.AU), Intuitive Surgical Inc (ISRG), Ypsomed Holding AG (YPSN.SW), Tecan Group AG (TECN.SW), MiniMed Group, Inc. Common Stock (MMED), EssilorLuxottica S. A. (EL.PA), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM) and others.

How does MDLN score against its peers?

Medline Inc. Class A Common Stock's composite reads 44/100, ranking 9 of 10 in its cohort as of 2026-10-12; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Medical Instruments & Supplies. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.